Haemonetics (HAE)
(Delayed Data from NYSE)
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
AMN Healthcare (AMN) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
AMN Healthcare's (AMN) first-quarter results are likely to reflect solid demand in some of the areas of its business.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at the Diagnostics segment.
AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
What's in Store for West Pharmaceutical's (WST) Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter results are likely to reflect strength in the Proprietary Products business.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.
Stryker (SYK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances.
Baxter (BAX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.
What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment.
Here's Why You Should Hold on to Haemonetics (HAE) For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.
Haemonetics' (HAE) Hospital Business Grows, Cost Ails Stay
by Zacks Equity Research
Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.
Haemonetics (HAE) Up 4.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.
Haemonetics (HAE) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.
Haemonetics (HAE) Q3 Earnings Beat Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 12% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Haemonetics (HAE) Ahead of Earnings?
by Zacks Equity Research
Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Haemonetics (HAE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Haemonetics (HAE) Stocks for Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.
Haemonetics (HAE) Q2 Earnings Lag Estimates, Gross Margin Grows
by Zacks Equity Research
Haemonetics (HAE) revenues increased year over year in the fiscal second quarter, supported by recovery across major businesses, especially Hospital and the initial Plasma Persona rollouts.
Haemonetics (HAE) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of -4.76% and -2.44%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on strong demand for NexSys PCS system and potential of Hemostasis Management franchise.
Haemonetics (HAE) Rides on Plasma Arm Recovery Amid COVID Woes
by Zacks Equity Research
Haemonetics' (HAE) hospital business is recovering primarily driven by continued improvement in hospital procedures.
Why Is Haemonetics (HAE) Up 4.9% Since Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.